Cited by 723HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHIV Research and Treatment

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

Open access

Venter, Willem D.F., Moorhouse, Michelle, Sokhela, Simiso, Fairlie, Lee, Mashabane, Nkuli, Masenya, Masebole, Serenata, Celicia, Akpomiemie, Godspower, Qavi, Ambar, Chandiwana, Nomathemba, Norris, Shane, Chersich, Matthew, Clayden, Polly, Abrams, Elaine, Arulappan, Natasha, Vos, Alinda, McCann, Kaitlyn, Simmons, Bryony, Hill, Andrew·2019·New England Journal of Medicine

DOI 10.1056/nejmoa1902824

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Two drugs under consideration for inclusion in antiretroviral therapy (ART) regimens for human immunodeficiency virus (HIV) infection are dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF). There are limited data on their use in low- and middle-income countries. METHODS: We conducted a 96-week, phase 3, investigator-led, open-label, randomized trial in South Africa, in which we compared a triple-therapy combination of emtricitabine (FTC) and DTG plus either of two tenofovir prodrugs - TAF (TAF-based group) or tenofovir disoproxil fumarate (TDF) (TDF-based group) - against the local standard-of-care regimen of TDF-FTC-efavirenz (standard-care group). Inclusion criteria included an age of 12 years or older, no receipt of ART in the previous 6 months, a creatinine clearance of more than 60 ml per minute (>80 ml per minute in patients younger than 19 years of age), and an HIV type 1 (HIV-1) RNA level of 500 copies or more per milliliter. The primary end point was the percentage of patients with a 48-week HIV-1 RNA level of less than 50 copies per milliliter (as determined with the Snapshot algorithm from the Food and Drug Administration; noninferiority margin, -10 percentage points). We report the primary (48-week) efficacy and safety data. RESULTS: A total of 1053 patients underwent randomization from February 2017 through May 2018. More than 99% of the patients were black, and 59% were female. The mean age was 32 years, and the mean CD4 count was 337 cells per cubic millimeter. At week 48, the percentage of patients with an HIV-1 RNA level of less than 50 copies per milliliter was 84% in the TAF-based group, 85% in the TDF-based group, and 79% in the standard-care group, findings that indicate that the DTG-containing regimens were noninferior to the standard-care regimen. The number of patients who discontinued the trial regimen was higher in the standard-care group than in the other two groups. In the per-protocol population, the standard-care regimen had equivalent potency to the other two regimens. The TAF-based regimen had less effect on bone density and renal function than the other regimens. Weight increase (both lean and fat mass) was greatest in the TAF-based group and among female patients (mean increase, 6.4 kg in the TAF-based group, 3.2 kg in the TDF-based group, and 1.7 kg in the standard-care group). No resistance to integrase inhibitors was identified in patients receiving the DTG-containing regimens. CONCLUSIONS: Treatment with DTG combined with either of two tenofovir prodrugs (TAF and TDF) showed noninferior efficacy to treatment with the standard-care regimen. There was significantly more weight gain with the DTG-containing regimens, especially in combination with TAF, than with the standard-care regimen. (ADVANCE ClinicalTrials.gov number, NCT03122262.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1902824

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215541 · Cited by 876
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel
Saag, M. S., Benson, C. A., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Mugavero, M. J., Sax, P. E., Smith, D. M., Thompson, M. A., Buchbinder, S. P., et al. (2018) · JAMA · doi:10.1001/jama.2018.8431 · Cited by 698
Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe
Mika Kivimaki, B., Kuosma, E., Ferrie, J. E., Luukkonen, R. A., Nyberg, S. T., Alfredsson, L. S., Batty, G. D., Brunner, E. J., Fransson, E. I., Goldberg, M., et al. (2017) · The Lancet Public Health · doi:10.1016/s2468-2667(17)30074-9 · Cited by 695
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Sax, P. E., Pozniak, A., Montes, M., Koenig, E., DeJesus, E., Stellbrink, H.-J., Antinori, A., Workowski, K., Slim, J., Reynes, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32340-1 · Cited by 394
Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception
Zash, R., Makhema, J. M., & Shapiro, R. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1807653 · Cited by 379
Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based Regimens
Norwood, J., Turner, M. M., Bofill, C., Rebeiro, P. F., Shepherd, B. E., Bebawy, S. S., Hulgan, T., Raffanti, S. P., Haas, D. W., Sterling, T. R., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001525 · Cited by 285
Brief Report
Walmsley, S. L., Baumgarten, A., Berenguer, J., Felizarta, F., Florence, É., Khuong-Josses, M.-A., Kilby, J. M., Lutz, T., Podzamczer, D., Portilla, J., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000790 · Cited by 225
Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis
Kanters, S., Vitória, M., Doherty, M. C., Socias, M. E., Ford, N. P., Forrest, J. I., Popoff, E., Bansback, N. J., Nsanzimana, S., Thorlund, K., et al. (2016) · The Lancet HIV · doi:10.1016/s2352-3018(16)30091-1 · Cited by 210
Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors
Bakal, D. R., Coelho, L. E., Luz, P. M., Clark, J. L., Boni, R. B. D., Cardoso, S. W., Veloso, V. G., Lake, J. E., & Grinsztejn, B. G. J. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky145 · Cited by 188
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Wohl, D. A., Yazdanpanah, Y., Baumgarten, A., Clarke, A. E., Thompson, M., Brinson, C. C., Hagins, D. P., Ramgopal, M. N., Antinori, A., Wei, X., et al. (2019) · The Lancet HIV · doi:10.1016/s2352-3018(19)30077-3 · Cited by 168

Flagged first, then by citations

Show all 31 references

Research works printed but not linked: 2

Doherty M. New directions in the 2015 WHO Consolidated ARV Guidelines: testing new directions in treatment and measuring impact. Presented at the Eighth International AIDS Society Conference Vancouver BC Canada July 19–22 2015.
Beyrer C, Pozniak A. HIV drug resistance. N Engl J Med 2018;378:875-875.29490186

Sorted by citations

Items 601–700 of 719

ANÁLISE DA MICROBIOTA VAGINAL BACTERIANA EM MULHERES NA PÓSMENOPAUSA QUE NÃO FORAM SUBMETIDAS À TERAPIA HORMONAL
Rodrigues, B. G., Modenese, I. B., Mattede, M. D. G. S., & Filho, A. C. (2020) · Estudos Interdisciplinares em Ciências Sociais e da Saúde · doi:10.5935/2675-7397.20200001
O índice de peritonite de mannheim na predição do desfecho pó-operatório da peritonite
Gueiros, L. D. S., da Fonseca, C. M., DUARTE, N. M. D. M., & ANTUNES, O. S. (2020) · Estudos Interdisciplinares em Ciências Sociais e da Saúde · doi:10.5935/2675-7397.20200013
Tenofovir Disoproxil Fumarate-Lowering Lipid Effects Moderately Protect Liver during Long-Term Antiretroviral Therapy in HIV-Infected Patients
Ouyang, L., Hong, Z. S., Dong, W., Zhu, H. Q., Li, Y., & Peng, X.-M. (2020) · Journal of AIDS & Clinical Research
Antiretroviral Drug Recommendations for HIV Treatment and Prevention
Shalev, N., Brudney, K. F., & Scherer, M. L. (2021) · JAMA · doi:10.1001/jama.2020.25987
Aumento di peso nelle persone che vivono con HIV: ultimi aggiornamenti da CROI 2021.
Colpani, A., & al., E. (2021) · JHA - Journal of HIV and Ageing · doi:10.19198/jha31513
HIV-Therapie – ein Überblick
Skoll, M. (2021) · hautnah · doi:10.1007/s12326-021-00450-w
Preditores de excesso de peso em pessoas que vivem com HIV em uso de TARV: aspectos nutricionais, clínicos, sociodemográficos e comportamentais
Cunha, R. L. (2021) · doi:10.34019/ufjf/di/2021/00167
UGT1A1 Regulatory Variant with Potential Effect on Efficacy of HIV and Cancer Drugs Commonly Prescribed in South Africa
Mathew, J. M., Mpangase, P. T., Sengupta, D., Kwenda, S., Mavri‐Damelin, D., & Ramsay, M. (2021) · Pharmacogenomics · doi:10.2217/pgs-2021-0062
L’aumento di peso nei pazienti che vivono con infezione da HIV: analisi retrospettiva di 10 anni di monitoraggio in una ...
Bartalucci, C. (2021) · JHA - Journal of HIV and Ageing · doi:10.19198/jha31524
Estimated global cost of treating COVID-19, HIV, Hepatitis B and Hepatitis C with approved effective oral medicationsPreprint
Ellis, L., Wang, J., Pilkington, V., Levi, J., Heath, K., & Hill, A. (2022) · Research Square · doi:10.21203/rs.3.rs-1606136/v1
Self-citation
Association of Latin-American Ethnicity with an Increase in Weight in an HIV-Infected Outpatient Population
(2022) · doi:10.31038/idt.2022312
Management of hypercholesterolemia in individuals living with HIV/AIDS
Ahmed, M., Ahmed, M., Mital, D., & Ahmed, M. H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00006-7
Combined cART Including Tenofovir Disoproxil, Emtricitabine, and Dolutegravir Has Potent Therapeutic Effects in HIV-1 Infected Humanized MicePreprint
Weichseldorfer, M. R., Affram, Y., Heredia, A., Tehrani, Z. R., Sajadi, M. M., Williams, S., Tagaya, Y., Benedetti, F., Ramadhani, H. O., Denaro, F., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-915826/v1
Novità in tema di incremento ponderale in persone con HIV in trattamento con Inibitori dell’Integrasi (INSTI).
Zauli, B., & al., E. (2022) · JHA - Journal of HIV and Ageing · doi:10.19198/jha31532
Prescribing Antiretroviral Therapy
Mathur, P., Bandres, M. V., Ajmal, S., Temesgen, Z., & Koren, D. E. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780197576595.003.0025
ANALYSIS OF THE METABOLIC SYNDROME AND ITS ASSOCIATION WITH CART IN HIV POSITIVE INDIVIDUALS RECEIVING VARIOUS CART REGIMENS WITH REVIEW OF LITERATURE.
Joshi, K., Saraf, U. U., & Gujarathi, R. (2022) · INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH · doi:10.36106/ijsr/7403793
Assessment of cardiovascular risk factors in obese women with HIV
Ali, M. W., Ayanbisi, I. O., Adamu, S., Sa’ad, F. K., Musa, M. S., & Ayoola, Y. A. (2022) · International Journal of STD & AIDS · doi:10.1177/09564624221132626
Identificação de novas moléculas orgânicas pelo uso combinado de experimentos de RMN e cálculos computacionais de DFT
Pinto, B. N. S. (2022) · doi:10.47328/ufvbbt.2022.588
Highlights from the 30th Conference on Retroviruses and Opportunist Infections (CROI)
Psomas, K. C., Barber, T., Kogilwaimath, S., & Waters, L. J. (2023) · Journal of Virus Eradication · doi:10.1016/j.jve.2023.100324
Tenofovir alafenamide and weight: What do we still need to know to inform clinical decisions?
Surial, B., & Wandeler, G. (2023) · HIV Medicine · doi:10.1111/hiv.13497
ĐÁNH GIÁ HIỆU QUẢ CỦA PHÁC ĐỒ ACRIPTEGA TRONG NĂM ĐẦU TIÊN TRÊN NGƯỜI NHIỄM HIV CHƯA TỪNG ĐIỀU TRỊ ARV
Nguyễn, T. H. D., Nguyễn, T. D., & Phạm, T. T. (2023) · Tạp chí Truyền nhiễm Việt Nam · doi:10.59873/vjid.v1i41.238
I nuovi farmaci antidiabetici nelle persone che vivono con l’infezione da HIV.
Mirani, M. (2023) · JHA - Journal of HIV and Ageing · doi:10.19198/jha31553
Prescribing Antiretroviral Therapy
Mathur, P., Mudroch, S., Ajmal, S., Temesgen, Z., & Koren, D. E. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197679098.003.0018
Antiretroviral Regimen and Pregnancy Outcomes of Women Living With Human Immunodeficiency Virus in a US Cohort
Kopp, C. M., Sobhani, N. C., Baker, B., Tapia, K. A., Jain, R., Hitti, J. E., & Roxby, A. C. (2023) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000001308
Comparing Safety and Effectiveness of Antiretroviral Therapy in a Diverse Population of Older People With HIV
Chahine, E. B., Nunez-Medina, R. M., Williams, K., Kuretski, J., & Maarsingh, H. (2023) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2023.472
Revisiting efavirenz in the era of dolutegravir: Low-dose efavirenz, a viable alternative capable of holding its own against dolutegravir-based regimens
Arora, S., Ashta, K. K., Anilkumar, A., & Raman, N. (2023) · Current Medicine Research and Practice · doi:10.4103/cmrp.cmrp_98_23
Contemporary Treatment Approaches for Human Immunodeficiency Virus Infection
Shroba, J., & Januszka, J. E. (2024) · Nursing Clinics of North America · doi:10.1016/j.cnur.2024.01.004
Demographic, Behavioural and Clinical Characteristics of HIV-infected Adults Initiating Antiretroviral Therapy in Rural ART Clinics in the Centre Region of Cameroon
Pangwoh, Y. Z., Tshuma, N., Etah, E., Chafa, N. A., Florentine, T. M., & Kouanfack, C. (2024) · Texila international journal of public health · doi:10.21522/tijph.2013.12.01.art015
Impact of Dolutegravir-based Regimen on Tolerance and Virologic Suppression, Compared to Non-dolutegravir Regimen among PLHIV in Southern Senegal
Diallo, K., Mbengue, D., Sarr, H., Badiane, A., Diallo, K., Coly, M. N., Badji, L. A., Wembulua, B. S., Diallo, K. M., Diatta, A., et al. (2024) · Asian Journal of Research in Infectious Diseases · doi:10.9734/ajrid/2024/v15i3336
Diabetes Mellitus–Tuberculosis Comorbidity in Low–Resource Settings
Williams, V. (2024) · doi:10.33540/2234
Commercial trials of medicinal products; other types of interventions; health economic analysis
Hackshaw, A. K. (2024) · Wiley eBooks · doi:10.1002/9781119502678.ch8
Impact of the COVID-19 pandemic on BMI in youth living with HIV
Mogasala, S., Helzer, C., Welch, R. D., Secord, E. A., & McGrath, E. J. (2024) · SAGE Open Medicine · doi:10.1177/20503121241267081
Dolutegravir-based Treatment in HIV-infected Diabetics Requires Close Cardiovascular Monitoring: A Point of Concern
Pal, D. (2024) · Journal of Clinical Infectious Disease Society · doi:10.4103/cids.cids_20_24
Comparative Metabolic Effects of Integrase Inhibitor and Emtricitabine-Containing Tenofovir Derivatives in People Living with HIV: A Multi-Center Retrospective AnalysisPreprint
Karabay, O., Vatan, A., Yılmaz, İ., Balta, N. C., Kantürk, A., Dumlu, R., Çağ, Y., Çaşkurlu, H., Şık, M. T., Aşık-Otman, Z., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4698296/v1
Nucleoside/nucleotide reverse transcriptase inhibitor-associated weight gain in people living with HIV: data from the Copenhagen Comorbidity in HIV Infection (COCOMO) study
Pedersen, K. B., Gelpi, M., Knudsen, A. D., Meddis, A., Suarez‐Zdunek, M. A., Afzal, S., Nordestgaard, B. G., Nielsen, S. D., & Benfield, T. (2024) · AIDS Care · doi:10.1080/09540121.2024.2383871
No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors
García‐Abellán, J., García, J. A., Padilla, S., Fernández‐González, M., Agulló, V., Mascarell, P., Botella, Á., Gutiérrez, F., & Masiá, M. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae383
Exploring the effects of time-restricted eating on body weight and associated cardiometabolic outcomes in South African women living with HIV (TESSA): protocol for a randomised controlled trial
Mendham, A. E., Goedecke, J. H., Heckens, L., Hoosen, F., Pico, M. L., Kengne, A. P., Christensen, D. L., Olesen, O. F., Quist, J. S., Dave, J. A., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-086203
Toward Evidence-based Recommendations for Laboratory Monitoring for Adolescents and Adults on Antiretroviral Therapy
Burman, W. J., & Hawkins, K. L. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae542
Costs of home-delivered antiretroviral therapy refills for persons living with HIV: Evidence from a pilot randomized controlled trial in KwaZulu-Natal, South Africa
Tseng, A. S., Barnabas, R. V., van Heerden, A. C., Ntinga, X., & Sahu, M. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0003368
“Weight and See”: Initial Weight Gain After Starting Antiretroviral Therapy Is Not Associated With Antiretroviral Regimen Type and Does Not Predict Subsequent Weight Trajectory
Tseng, A. L.-I., Lovblom, L. E., & Walmsley, S. L. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae763
Dolutegravir/Abacavir/Lamivudine in Acute HIV-1 Results in Rapid Suppression and Restoration of CD4 T-cell Subsets Without Accelerated Decay of Latent HIV-1
Gay, C. L., Keys, J., Kuruc, J. D., Sponaugle, A. T., McGee, K. S., Ang, C., Baker, C., Weimer, E. T., Schmitz, J. L., Archin, N. M., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf247
Antiretroviral Therapy Selection/Decision-Making
Ajmal, S., Temesgen, Z., Mathur, P., & Koren, D. E. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197812631.003.0015
Factors Associated With Incomplete Adherence to Dolutegravir-Based Antiretroviral Therapy in Southwestern Uganda
Nutt, C. T., Muyindike, W. R., Nanfuka, V., Komukama, N., Barigye, I. T., Kansiime, L., Tumusiime, J., Omoding, D., Aung, T. N., Stuckwisch, A. M., et al. (2025) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003735
Disparities in screening, diagnosis, and treatment of diabetes mellitus among people with HIV at a large southeastern academic health center
Millman, N., Koethe, J. R., Turner, M. M., Bourgi, K., Sterling, T. R., & Rebeiro, P. F. (2025) · HIV Research & Clinical Practice · doi:10.1080/25787489.2025.2551399
Three-Year Outcomes After Programmatic Transitioning to Dolutegravir in the Context of Severe Civil Unrest in Haiti
Liautaud, B., Chico, A. S., Macius, Y., Abuhay, S., Joseph, P., Reeder, H. T., Bolas, T., Marcelin, A., Guiteau, C., Apollon, A., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf526
No changes in weight, body composition or metabolic parameters after the switch to dolutegravir and lamivudine compared to continued treatment with dolutegravir, abacavir and lamivudine for virologically suppressed HIV infection (The AVERTAS trial)
Heje, K. B., Lindhardt, M. S., Meddis, A., Knudsen, A. D., Kronborg, G., Weis, N. M., Lebech, A., Kirk, O., Helweg‐Larsen, J., Helms, M., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11334-2
Maternal Anthropometry, Body Composition, and Fat Distribution by HIV Status and Antiretroviral Therapy Class in South African Women
Madlala, H. P., Myer, L., Geffen, H., Jao, J. K., Matjila, M. J., Fisher, A., Meyer, D., Dugas, L. R., Mendham, A. E., Petro, G. A., et al. (2025) · AIDS Research and Human Retroviruses · doi:10.1177/08892229251374692
Antiretroviral Therapy-Associated Weight Gain in Mexico, a Country Prone to Comorbidities
Tapia-Maltos, A., & Crabtree‐Ramírez, B. (2025) · International Journal of Health Policy and Management · doi:10.34172/ijhpm.9004
Prevalence and risk factors of stroke in patients with HIV infection
Yusupov, F. A., Токтосунович, Ы. И., & Yuldashev, A. A. (2025) · Clinical Medicine (Russian Journal) · doi:10.30629/0023-2149-2025-103-5-333-338
Obesity and adherence to recommended fruits and vegetable intake among the HIV-positive population in ZambiaPreprint
Bwembya, P. A., Chavula, M. P., Somwe, P., Zyambo, C. M., Halwindi, H., Mandyata, C., Phiri, H., Meki, C. D., & Kaliwile, C. (2025) · Research Square · doi:10.21203/rs.3.rs-7851833/v1
Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes
Patel, K., Jaramillo-Underwood, A., Karalius, B., Yao, T., Dyke, R. B. V., Mirza, A., Jao, J. K., Agwu, A. L., (PHACS), F. T. P. H. C. S., CHADWICK, E. G., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf538
Magnitude and factors associated with virological failure among adults on first-line antiretroviral therapy in Dire Dawa, eastern Ethiopia: a retrospective chart review
Tesema, K., Edessa, D., Cheru, A., & Mengesha, M. M. (2025) · BMC Research Notes · doi:10.1186/s13104-025-07520-9
Pautas actuales de tratamiento de la infección por VIH
Arbaizar, J. F., Martínez, A. N., Revollo, B., & Llibre, J. M. (2025) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2025.01.007
Interactions between long-term Antiretroviral Therapy and Risk of Hypertension among People Living with HIV in an Urban HIV Clinic in Cameroon, 2024: A Case-control StudyPreprint
Nang, F. D. N., Kuate, L. M., Akoa, A. O., Chebo, P. J., Dzudié, A., Fankoua, L. B., Kengne, A. P., Tchitetchoun, J. P. J., Ifoue, R. M., Mbolueh, L. N., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7821718/v1
Undesired weight gain and associated healthcare outcomes among people living with HIV on antiretroviral therapy
Cambron‐Mellott, M. J., Tadese, B. K., Arduino, J. M., Balkaran, B. L., Eslamimehr, S., & Zuniga, J. M. (2025) · AIDS Care · doi:10.1080/09540121.2025.2585495
Can switching to doravirine/lamivudine/tenofovir DF halt or reverse INSTI-associated weight gain?
Tseng, A. L.-I., Loutfy, M. R., Thai, L., & Walmsley, S. L. (2025) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2025-0016
Challenges in HIV care at a tertiary hospital repurposed for COVID-19: an observational study (2019–2022)
Romero-Mora, K. A., Schjetnan, M. G.-P., Dávila‐Conn, V., García-Delgado, C. A., Cervantes-Valenzuela, M., la Barrera, C. A., Schulz‐Medina, S. E., & Ávila‐Ríos, S. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-12357-5
Additional file 1 of Combined cART including Tenofovir Disoproxil, Emtricitabine, and Dolutegravir has potent therapeutic effects in HIV-1 infected humanized mice
Weichseldorfer, M. R., Affram, Y., Heredia, A., Tehrani, Z. R., Sajadi, M. M., Williams, S., Tagaya, Y., Benedetti, F., Ramadhani, H. O., Denaro, F., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16909783
Additional file 2 of Gaps in the type 2 diabetes care cascade: a national perspective using South Africa’s National Health Laboratory Service (NHLS) database
Brennan, A. T., Lauren, E., Bor, J. H., George, J. A., Chetty, K., Mlisana, K., Dai, A., Khoza, S., Rosen, S. B., Stokes, A. C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26657329
Additional file 1 of Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV
Plum, P.-E., Maes, N., Sauvage, A.-S., Frippiat, F., Meuris, C., Uurlings, F., Lecomte, M., Léonard, P., Paquot, N., Fombellida, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16575956
Additional file 1 of Dynamics of HIV PrEP use and coverage during and after COVID-19 in Germany
Schmidt, D., Duport, Y., Kollan, C., Marcus, U., Iannuzzi, S., & von Kleist, M. (2024) · Figshare · doi:10.6084/m9.figshare.26103744
Additional file 2 of “It’s only fatness, it doesn’t kill”: a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda
Alhassan, Y. N., Twimukye, A., Malaba, T. R., Myer, L., Waitt, C., Lamorde, M., Colbers, A. P. H., Reynolds, H. E., Khoo, S., & Taegtmeyer, M. (2022) · Figshare · doi:10.6084/m9.figshare.20115581
Additional file 1 of “It’s only fatness, it doesn’t kill”: a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda
Alhassan, Y. N., Twimukye, A., Malaba, T. R., Myer, L., Waitt, C., Lamorde, M., Colbers, A. P. H., Reynolds, H. E., Khoo, S., & Taegtmeyer, M. (2022) · Figshare · doi:10.6084/m9.figshare.20115578
Additional file 1 of Dyslipidemia among adult people living with HIV on dolutegravir – based antiretroviral therapy at a private tertiary hospital in Kampala, Uganda: burden and determinants
Kigongo, V. J., Nankabirwa, J. I., Kitutu, F. E., Ssenyonga, R., Mutebi, R. K., Kazibwe, A., Kiguba, R., Kambugu, A. D., & Castelnuovo, B. (2024) · Figshare · doi:10.6084/m9.figshare.24953157
Additional file 1 of Gaps in the type 2 diabetes care cascade: a national perspective using South Africa’s National Health Laboratory Service (NHLS) database
Brennan, A. T., Lauren, E., Bor, J. H., George, J. A., Chetty, K., Mlisana, K., Dai, A., Khoza, S., Rosen, S. B., Stokes, A. C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26657326
Foundation models enable wearable signal screening for cardiovascular disease among people living with HIV
Mesinovic, M., Hai, H. B., Triều, L. V., Quốc, V. N., Thanh, N. N., Hoang, T. A., Hoang, M. T. V., Khanh, P. N. Q., Huy, V. X., Vo, H.-P., et al. (2026) · Communications Medicine · doi:10.1038/s43856-025-01331-6
Transcriptional response to combination antiretroviral therapy predicts side effects and novel targets
Lachmann, A., Amadori, L., Nicoletti, P., Crane, H. M., Giannarelli, C., Avi, M., & Peter, I. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1743543
Vitamin D Deficiency and Bone Turnover in People Living With HIV Switching to Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir Versus Continuing Nonnucleoside Reverse Transcriptase Inhibitor or Protease Inhibitor Regimens in Thailand
Praisarnti, P., & Patamatamkul, S. (2026) · Research Medical Journal · doi:10.33165/rmj.2026.e274510
The effect of Biktarvy (B/F/ TAF ) on whole‐body insulin sensitivity, lipid and endocrine profile in healthy volunteers
Heskin, J., Movahedi, R., Kang, S., Byrne, R., Elecito, K., Gridel, P., Marchesani, P., Moyle, G. J., Milinkovic, A., & Boffito, M. (2026) · HIV Medicine · doi:10.1111/hiv.70208
Exploring the Relationship Between Dolutegravir and Diabetes Using Routine Data of Patients on Anti-Retroviral Treatment in a High HIV Prevalence Setting
Haumba, S., Maseko, T., Khumalo, F., Mndzebele, N., Nyapokoto, C. M., & Ojoo, S. A. (2025) · Medical Research Archives · doi:10.18103/mra.v14i2.7309
Evaluation of the relevance, acceptability, and adaptability of an existing healthy lifestyle program for people living with HIV
Hill, J., Skinner, D. G., Goedecke, J. H., van Rensburg, R., Schalkwyk, M. V., Nachega, J. B., & Kengne, A. P. (2026) · BMC Public Health · doi:10.1186/s12889-026-26991-4
Viral load non-suppression and associated factors among HIV patients receiving fixed dose combination therapy at Jayapura City, Papua, Indonesia
Widiyanti, M., Nasronudin, N., Lusida, M. I., Sunarno, S., Sandy, S., & Khairunisa, S. Q. (2026) · Acta Tropica · doi:10.1016/j.actatropica.2026.108055
Metabolic impact of switching from EFV/TDF/FTC to two INSTI-Based regimens (B/F/TAF vs. DTG/3TC): a real-world study in virologically suppressed individuals
Li, E., Wang, Y., Yan, D., Shi, J., Yu, J., Hu, X., & Zhang, W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1753242
Formes circulantes du virus de l’hépatite B et nouveaux marqueurs viraux
Pronier, C. (2020) · doi:10.70675/913878f3zc5c3z493fz9c77ze2e4e974cb56
Retention in HIV care before and after implementation of a case management program in Malawi
Makonokaya, L., Dunga, S., Kalitera, L. U., Chamanga, R. K., Msuku, L., Golowa, C., Joaki, Z., Sankhani, A., Singini, G. C., Makoko, S., et al. (2026) · BMC Public Health · doi:10.1186/s12889-026-27295-3
Défis de la prise en charge du VIH en Afrique de l'Ouest à l'ère du traitement pour tou.te.s : analyses épidémiologiques du continuum de soins et des évènements de santé, avec une perspective de genre
Tiendrebeogo, T. (2023) · theses.fr (ABES) · doi:10.70675/0766a153zda7dz4199zb0e4z4e19848b88b9
Hypertension in a Randomized Trial of Dolutegravir- Versus Efavirenz-Based Antiretroviral Therapy in Pregnant and Postpartum Women with HIV
Hoffman, R. M., Brummel, S. S., Pinilla, M., Malonga, G. P., Chinula, L., Stranix‐Chibanda, L., Machado, E. S., Naik, S., Rathore, M. H., Pilotto, J. H., et al. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag245
Self-citation
Biological Profile of People Living with HIV under Antiretroviral Therapy at the Ambulatory Treatment Center in Dakar, Senegal
Thiam, M., Thiam, S., Ngom, N. F., Faye, A., Sow, H. O., Faye, A., Fall, B., Ndiaye, A., Diao, I., Kandji, P. M., et al. (2026) · Pharmacology & Pharmacy · doi:10.4236/pp.2026.173008
Subclinical atherosclerosis assessed by cardio-ankle vascular index and carotid intima–media thickness in people living with HIV receiving integrase inhibitor–based tenofovir regimens
Vatan, A., Karabay, O., Moralı, H., Kara, Y., Güçlü, E., Öğütlü, A., & Vatan, M. B. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13377-5
Prevalence of Hyperlipidemia and Associated Factors Among People Living With HIV Attending Care at Rugazi Health Center IV, Rubirizi District South-Western Uganda
Mwikiriize, M., Kaizirege, F., Nekejju, W. G., Mnyeti, J. M., Mgaya, P. O., Bagenda, C. N., Mugume, I. B., & Mbalibulha, Y. (2026) · Journal of the International Association of Providers of AIDS Care (JIAPAC) · doi:10.1177/23259582261456428
Prevalence and Correlates of Steatotic Liver Disease Among People With HIV in Uganda
Bibangambah, P., Acan, M., Ghoshhajra, B. B., Erem, G., Nassanga, R., Ochieng, A., Thondapu, V., Lu, M. T., Randhawa, M., Takigami, A. K., et al. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag325
The impact of dolutegravir on the growth of HIV-exposed uninfected infants: an observational cohort study in rural Tanzania
Glanzmann, S., Luoga, E., Okuma, J. O., Dotto, E., Sigalla, G., Franzeck, F. C., Nyenza, E., Mnzava, D., Bukuku, M., Moshi, L., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103984
The Gut–Immune Axis in Treated HIV Infection: From Mucosal Damage to Chronic Inflammation and Therapeutic Opportunities—A Clinician-Oriented Narrative Review
Nitsotolis, T. N., Assimakopoulos, S. F., Lagadinou, M., Papalexandrou, A., Krikis, N., Kourtidis, M., Christaki, E., & Milionis, H. J. (2026) · Microorganisms · doi:10.3390/microorganisms14061229
Trends in Human Immunodeficiency Virus Care Outcomes among Key Populations: Evidence from High-Burden States
Ochonye, B. B., Abang, R., Sanni, O. F., Emenike, K., Umoh, P., & Kalaiwo, A. (2026) · Journal of Comprehensive Health · doi:10.25259/jch_19_2025
HIV-Related Stigma and Its Impact Across the HIV Care Continuum: Implications for Testing, Treatment, and Long-Term Retention
Somji, S., Ngimbwa, J., Kahwa, T., Ali, R., Elias, C., Ebrahim, F. A., Shah, R., Sharma, M., & Surani, S. (2026) · Cureus · doi:10.7759/cureus.110535
Evaluation of Calcium Levels Among HIV Patients Attending RSUTH: ART- Naïve Versus ART Experienced
Waribo, H. A., Meniel, A., & Ogu-Nweke, E. (2026) · American Journal of Biomedical and Life Sciences · doi:10.11648/j.ajbls.20261403.11
Longitudinal Weight Gain Trajectories After Initiation of Dolutegravir‐Based Antiretroviral Therapy: A Retrospective Cohort Study
Akanit, U., Boonlue, T., Poonphol, P., Maneekanon, T., Donganon, P., Suebsin, J., & Dawvongyad, N. (2026) · AIDS Research and Treatment · doi:10.1155/arat/4740293
Human immunodeficiency virus and acquired immunodeficiency syndrome in women
Jones, J. L., & Scully, E. P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45863-7.00045-7
Factors associated with prevalent hypertension among adults living with HIV receiving antiretroviral therapy in Yaounde, Cameroon: a cross-sectional study
Nang, F. D. N., Kuate, L. M., Chebo, P. J., Dzudie, A., Fankoua, L. B., Kengne, A. P., Tchitetchoun, J. P. J., Akoa, F. A. O., Ifoue, R. M., Mbolueh, L. N., et al. (2026) · AIDS Research and Therapy · doi:10.1186/s12981-026-00905-1
Metabolic and Immunological Trajectories and Virological Outcomes of Ainuovirine‐Based Antiretroviral Therapy: A 48‐Week Longitudinal Cohort Study in Treatment‐Naïve Adults
Gan, L., Xie, X., Fu, Y., Yang, X., Ma, S., Song, C., Song, Y., Ren, T., & Long, H. (2026) · Journal of Medical Virology · doi:10.1002/jmv.71038
Molecular Characterization of HIV-1 Subtypes and Primary Drug Resistance Mutations in Bangladesh: Insights from 2019 Data
Molla, M. A., Sultana, N., Disha, J. A., Nafisa, T., Yeasmin, M., Raihan, R., Tabassum, S., & Munshi, S. U. (2026) · The Open AIDS Journal · doi:10.2174/0118746136419186260624054535
Viral Load Profile at the Efavirenz-Dolutegravir Switch: A Case Study of the Center of Excellence for the Care of People Living with HIV/AIDS at the University of Lubumbashi, Democratic Republic of Congo
Kambote, A. K., Éric, K. I., Pierre, M. M., Lukamba, J. N., Dodo, M. M., Frank, K. T., Emmanuel, T. M., Michel, B. E., & Philomene, L. A. (2026) · World Journal of AIDS · doi:10.4236/wja.2026.163004
Virological impact of the programmatic dolutegravir transition at Mildmay Hospital Uganda: a before-and-after cohort study with subgroup and trajectory analysis, 2016–2023
Asiku, R. A., Sserunjogi, C., Ankunda, C., Nakubulwa, S. K., Mwaka, J., Muluga, W. U., Musoki, D., Kukundakwe, P., & Mulebeke, R. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13976-2
Antiretroviral Therapies and MASLD: Weight Gain, Insulin Resistance and Hepatic Steatosis
Mermutluoğlu, Ç., & Çelen, M. K. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016844
Do They, or Don't They? Integrase Strand Transfer Inhibitors, Tenofovir Alafenamide, and Excessive Weight Gain in People With HIV
Wohl, D. A. (2026) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiag365
Pretreatment HIV-1 drug resistance and molecular subtype characteristics among newly diagnosed individuals in Guangxi, China
Chen, G., Hu, M., Pan, Y., 黄丽花, Dou, Y., Sui, W., Tang, Y., Chen, J., & Liu, A. (2026) · AIDS Research and Therapy · doi:10.1186/s12981-026-00924-y
Projected burden of hypertension-associated cardiovascular disease in people living with HIV versus HIV-negative adults in EswatiniPreprint
Milali, M. P., Citron, D., Bhamidipati, K., Yamamoto, N., Osei-Ntansah, A., Platais, I., Ferrara, G., Ngcamphalala, C., Dlamini, S. G., Ginindza, N. M., et al. (2026) · medRxiv · doi:10.64898/2026.07.17.26358301
Transition to generic dolutegravir: immunologic, virologic, and metabolic outcomes in a resource-limited setting
AbdelMagid, A. M., Cordie, A., Mohamed, R., Fahmy, H., Khateeb, E. E., Tamim, H. H., Elsaadany, Z., Masoud, Z., Esmat, G., & Kamel, A. M. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05766-z
Nutritional status and functional capacity among people living with HIV in routine care: a retrospective cohort study
Odeigah, L. O., Ologe, M. O., Oshikoya, K. A., & Fadare, J. O. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1851353
A retrospective evaluation of anti-retroviral therapy regimen modifications due to adverse drug reactions in a tertiary care hospital
K., D. K., Ahmed, S. M., & Basavanna, P. L. (2026) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20262855

Authors: Venter, W. D. F., Moorhouse, M., Sokhela, S., Fairlie, L., Mashabane, N., Masenya, M., Serenata, C., Akpomiemie, G., Qavi, A., Chandiwana, N., Norris, S., Chersich, M., Clayden, P., Abrams, E., Arulappan, N., Vos, A., McCann, K., Simmons, B., & Hill, A.
Affiliations: From Ezintsha (W.D.F.V., M. Moorhouse, S.S., N.M., C.S., G.A., N.C., N.A., A.V.), Wits Reproductive Health and HIV Institute, Faculty of Health Sciences (W.D.F.V., M. Moorhouse, S.S., L.F., N.M., M. Masenya, C.S., G.A., N.C., M.C., N.A., A.V.), and the South African Medical Research Council Developmental Pathways for Health Research Unit, Department of Pediatrics, School of Clinical Medicine, Faculty of Health Sciences (S.N.), University of the Witwatersrand, Johannesburg; the Faculty of Medicine,...
South African Medical Research Council (ZA)
ORCID: Venter, Willem D.F.
Moorhouse, Michelle
Sokhela, Simiso
Fairlie, Lee
Mashabane, Nkuli
Masenya, Masebole
Serenata, Celicia
Akpomiemie, Godspower
Qavi, Ambar
Chandiwana, Nomathemba
Norris, Shane
Chersich, Matthew
Clayden, Polly
Abrams, Elaine
Arulappan, Natasha
Vos, Alinda
McCann, Kaitlyn
Simmons, Bryony
Hill, Andrew
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2019-08-29
Volume: 381
Issue: 9
Pages: 803-815
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1902824
OpenAlex: W2962964639
Cited by: 723
References: 31
Citations by year: 2026: 65 · 2025: 84 · 2024: 117 · 2023: 110 · 2022: 90 · 2021: 112 · 2020: 120 · 2019: 25
FWCI: 66.47
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
ePrints Soton (University of Southampton) (submittedVersion)
Spiral (Imperial College London) (submittedVersion)
Utrecht University Repository (Utrecht University) (submittedVersion)
Funders: UNITAID (2016-07-Wits RHI)
U.S. Agency for International Development (AID-OAA-A-15-00069)
South African Medical Research Council
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords: dolutegravir, tenofovir alafenamide, tenofovir disoproxil fumarate, HIV-1 infection, antiretroviral therapy, triple therapy, emtricitabine, efavirenz, non-inferiority, viral suppression, treatment discontinuation, low- and middle-income countries, South Africa
MeSH terms: Dolutegravir, Adenine, Adolescent, Adult, Drug Therapy, Combination, Female, Heterocyclic Compounds, 3-Ring, Humans, Male, Middle Aged, Oxazines, Phosphorous Acids, Piperazines, Pregnancy, Pregnancy Complications, Infectious, Prodrugs, Pyridones, RNA, Viral, Uracil, HIV-1, Bone Density, HIV Infections, CD4 Lymphocyte Count, HIV Integrase Inhibitors, Viral Load, Anti-Retroviral Agents, Young Adult, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks